Skip to main content

Table 6 Improvement in functioning and patient impression of illness improvement

From: A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine

  Galcanezumab 120 mg Galcanezumab 240 mg
N Mean (SE) or % N Mean (SE) or %
MSQ RF-R, mean increase (improvement) 130 31.6 (1.2) 135 33.4 (1.2)
MIDAS total, mean decrease (improvement) 124 −33.6 (2.1) 130 −32.7 (2.0)
Patient Global Impression – Illness Improvement at Month 12 90 112
 Very much better   52.2%   52.7%
 Much better   27.8%   32.1%
 A little better   15.6%   7.1%
 No change   3.3%   7.1%
 A little worse   1.1%   0.9%
 Much worse   0%   0%
 Very much worse   0%   0%
  1. MIDAS Migraine Disability Assessment, MSQ RF-R Migraine-Specific Questionnaire Role Function – Restrictive, SE standard error